> 首页 > 产品 > 一抗 > 基因重组 > Anti-TROP2 Reference Antibody (Sacituzumab-MMAE)

Anti-TROP2 Reference Antibody (Sacituzumab-MMAE)

Recombinant Antibody

Anti-TROP2 Reference Antibody (Sacituzumab-MMAE) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.
The purity of Anti-TROP2 Reference Antibody (Sacituzumab-MMAE) is more than 95%, determined by SEC-HPLC.
Sacituzumab-ADC inhibited the tumor growth of MDA-MB-231 on NSG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 80.0% at 5 mpk at D37.
Killing assay test on NCL-H292 Cells,the maximum kill rate of anti-TROP2 Reference Antibody (Sacituzumab MMAE) is about 100%.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P09758
Reactivity	Human
Clonality	ADC
Isotype	IgG1
Calculated MW	150 KDa

Additional Information
Target/Specificity	TROP2
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.